Literature DB >> 8717382

Clinical and immunological characteristics of the emulsion form of inactivated influenza vaccine delivered by oral immunization.

S S Avtushenko1, E M Sorokin, N Y Zoschenkova, N G Zacharova, A N Naichin.   

Abstract

Prophylaxis of human respiratory diseases caused by influenza viruses is actually a problem of infectious pathology because of their wide prevalence. In our investigations, safety, reactogenicity and immunological activity of the orally administered emulsion-inactivated influenza vaccine prepared from influenza virus strains of types A(H1N1), A(H3N2) and B have been studied. Clinical studies of the emulsion-inactivated influenza vaccine on volunteers has shown its safety and nonreactogenicity. The orally administered vaccine did not cause weak, middle or strong general or local reactions including clinical, biochemical, haemotological and immunological reactions. The emulsion-inactivated vaccine has high immunological activity and induces reliable increases in the level of secretory immunoglobulin A to influenza viruses A and B in protective titers in nasal secretions and saliva of volunteers after one oral administration. The obtained results indicate the expediency of further investigation and improvement of inactivated influenza vaccine for oral administration.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8717382     DOI: 10.1016/0168-1656(95)00105-0

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  3 in total

Review 1.  Non-invasive administration of biodegradable nano-carrier vaccines.

Authors:  Mohd Abul Kalam; Abdul Arif Khan; Aws Alshamsan
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

2.  Oral vaccination with inactivated influenza vaccine induces cross-protective immunity.

Authors:  Fu-Shi Quan; Richard W Compans; Sang-Moo Kang
Journal:  Vaccine       Date:  2011-11-19       Impact factor: 3.641

Review 3.  Microneedle and mucosal delivery of influenza vaccines.

Authors:  Sang-Moo Kang; Jae-Min Song; Yeu-Chun Kim
Journal:  Expert Rev Vaccines       Date:  2012-05       Impact factor: 5.217

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.